What is the real clinical treatment effect of Asciminib?

Asciminib (Asciminib) is a new type of targeted drug that is a selective BCR-ABL1 tyrosine kinase inhibitor. It is mainly used to treat chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (Ph+ ALL) and other leukemia types related to the BCR-ABL1 fusion gene. Aceminib plays a clinical therapeutic role by binding to the key domain of the BCR-ABL1 fusion protein, blocking its abnormal activation and inhibiting the proliferation and spread of tumor cells.

Clinical effects of Aceminib:

Clinical research on aximinin mainly focuses on its effect in the treatment of patients with chronic myelogenous leukemia (CML), especially those who have responded to traditional tyrosine kinase inhibitors (TKIsTKIs span>) such as imatinib (Imatinib) or dasatinib (Dasatinib) who develop resistance or intolerance. Studies have shown that Aceminib has significant efficacy in such patients, especially in drug-resistant patients, and can effectively reduce the number of leukemia cells and improve the survival of patients.

In a pivotal Phase III clinical trial (the ASCEMBL trial), aceminib was compared with imatinib as a first-line treatment for patients with CML. The results showed that aceminib was able to provide a higher molecular response rate (MR4.5response rate), that is, the patient's leukemia cells were almost completely eliminated. Data from this trial showed that aximinib was more effective than imatinib in patients with CML and was well tolerated, with no serious side effects or fatal events. In addition, aximinib can also play a good therapeutic role in patients who have failed imatinib, and some patients have recovered good molecular responses after treatment.

Efficacy in drug-resistant patients:

The efficacy of aceminib has also been verified in studies of drug-resistant patients. Many CML patients have received poor treatment results due to mutations or resistance mechanisms after several rounds of traditional TKIs treatment. Aceminib is different from other TKIsThe mechanism of action shows better efficacy in these patients. For example, in some CML patients, aciminib is effective against the T315I mutation, a common TKI resistance mutation, making aciminib an important option for treating TKIresistant patients.

For Ph+acute lymphoblastic leukemia (Ph+ ALL) patients, the clinical effect of aceminib has also been initially verified. Ph+ ALL is a type of leukemia closely related to the BCR-ABL1 fusion gene. It usually becomes resistant or relapses to traditional chemotherapy and TKIs treatment. Aceminib, a new targeted drug, has shown potential in these refractory patients. In small-scale clinical studies, aceminib has a good effect on Ph+ ALL patients and can help these patients regain remission.

Side effects and safety:

The side effects of aximini are relatively mild and mainly include the side effects of common tyrosine kinase inhibitor drugs, such as fatigue, headache, gastrointestinal discomfort, abnormal liver function, etc. Compared with other traditional TKIs, aceminib has a lower incidence of side effects and is tolerable in most patients. In some patients, hematological adverse reactions such as thrombocytopenia and leukopenia may occur, but most of these side effects are mild and can be relieved after reducing the dose or discontinuing the drug.

Overall, the real-life effects of aceminib in clinical treatment are satisfactory. For CML and Ph+ ALL patients, especially those who have developed resistance or intolerance to traditional TKIs, aceminib provides a new treatment option with better efficacy than some traditional drugs. Aceminib not only improves the clinical symptoms of these patients and prolongs survival, but also has milder side effects and better tolerance than traditional treatment drugs. With in-depth research on the clinical application of Aceminib, it is expected that its application prospects in the treatment of leukemia will be broader, bringing treatment hope to more patients.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib